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THE EFFECT OF VITAMIN D2, VITAMIN D3 OR  
 
VITAMIN D2 IN MUSHROOM POWDER SUPPLEMENTS ON 
 
BROAD GENE EXPRESSION IN HUMAN WHITE BLOOD CELLS 
 
CAROLINE ELIZABETH FEIGERT 
ABSTRACT 
 Sufficient vitamin D is important for overall health. However, cutaneous 
production of vitamin D is limited by season and little vitamin D naturally occurs in 
food. Therefore, vitamin D supplementation is necessary. Vitamin D is available 
in pharmacies as vitamin D2 and vitamin D3, and can also be obtained by 
irradiating mushrooms to produce vitamin D2. Types of vitamin D 
supplementation were tested to compare their ability to increase vitamin D status 
and their effect on broad gene expression in human white blood cells. 2000 IU of 
vitamin D2, vitamin D3 or vitamin D2 in irradiated mushroom powder were given to 
subjects daily for twelve weeks. A placebo mushroom powder group was 
included in the second half of the study. To determine the effect of different 
supplementation on vitamin D status, whole blood was obtained weekly and 
serum was assayed for 25(OH)D2 and 25(OH)D3. Change in total 25(OH)D was 
determined from baseline to twelve weeks; 25(OH)D levels in the placebo 
mushroom powder group did not change significantly at 1.8 ± 1.8 ng/ml (9.6 ± 
9.6%), the mushroom D2 group increased by 10.9 ± 10.2 ng/ml (53.2 ± 49.8%), 
the supplemental D2 group increased by 11.8 ± 7.4 ng/ml (60.2 ± 37.8%) and the 
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supplemental D3 group increased by 21.7 ± 8.9 ng/ml (114.2 ± 46.8%). As 
expected, the total active form of vitamin D (1,25-dihydroxyvitamin D) showed no 
change in all groups because of its tight regulation. To determine the potential 
influence of vitamin D supplementation on differential gene expression in the 
immune system, white blood cells were isolated from whole blood samples taken 
before and after supplementation. RNA was extracted, and microarray assays 
were performed. Gene Set Enrichment Analysis was completed to determine 
strongly influenced pathways. However, due to the numerous variables between 
halves of the study, gene expression data was treated as separate studies. Even 
so, pathways involving RNA activation and degradation were significant between 
mushroom powder and mushroom D2 supplementation in both halves of the 
study, indicating the influence of compounds in mushrooms on RNA metabolism 
pathways. Supplemental vitamin D2 affected gene expression, though only two 
pathways showed significant change. Supplemental vitamin D3 was found to 
influence pathways involved in replication, transcription, and translation in both 
halves of the study. In conclusion, mushrooms powder, mushroom vitamin D2, 
supplemental vitamin D2, and supplemental vitamin D3 all influence differential 
gene expression in human white blood cells.  
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INTRODUCTION 
 
Though included in its name, vitamin D is a hormone, not a vitamin. 
Vitamin D can be produced endogenously in the skin by exposure to sunlight or 
obtained through the diet. Two major forms of vitamin D exist; vitamin D3 is 
endogenous to animals, including humans, while plants and fungi generate 
vitamin D2. Both forms have important roles in the human body, primarily by 
regulating calcium balance and bone remodeling. However, vitamin D is now 
known to influence a wide variety of pathways throughout the body, including 
metabolism, immune response and cardiovascular health. Vitamin D deficiency 
has been correlated strongly with many human diseases, including obesity, 
multiple sclerosis, and cancer, while sufficient vitamin D status is strongly related 
to overall increased health. Understanding the mechanisms underlying vitamin D 
metabolism and activity will greatly enhance our comprehension of human 
disease as well as vitamin D’s evolutionary importance. 
 Early in the earth’s history, the sun’s rays bombarded the planet. Simple 
marine organisms evolved in the primordial soup, using the energy from the sun. 
In the marine environment, phytoplankton emerged. Some of these organisms, 
such as Emiliana huxlei, have remained unchanged for 750 million years. When 
grown in culture and exposed to simulated sunlight, E. huxlei converted their 
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endogenous ergosterol to vitamin D2, providing evidence that organisms could 
produce vitamin D that early in earth’s history (Holick and Garabedian, 2006).  
Several theories explaining the evolutionary advantage of vitamin D exist. 
First, the ultraviolet (UV) absorption spectra for provitamin D significantly 
overlaps with the spectra of UV-sensitive macromolecules. Most significantly, 
DNA and RNA suffer near irreparable damage from UV radiation, and provitamin 
D may have evolved as a natural sunscreen for the organisms’ genetic material. 
Second, the photoproducts from UV irradiation might have acted as indicators of 
total damaging radiation to the simple organisms (Holick et al, 2002).  
Furthermore, the extrusion of newly formed vitamin D from the plasma 
membrane of cells could have been the first calcium channel, due to the 
hypothetical pore formed when vitamin D exits the membrane (Holick and 
Garabedian, 2006).  
 Early aquatic organisms easily acquired the requisite calcium directly from 
the ocean to evolve structurally rigid vertebrate skeletons. However, when 
vertebrates began moving onto land, a new, efficient means of obtaining calcium 
from plants growing in calcium-rich soil was required to develop and maintain 
these endoskeletons (Holick et al, 2002). Increasing intestinal calcium absorption 
in early vertebrates was achieved through solar irradiation of 7-
dehydrocholesterol in the skin, producing vitamin D.  
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The first form of vitamin D isolated from ergosterol was designated vitamin 
D1. However, this nomenclature was discarded when researchers realized the 
material was actually a mixture of the desired vitamin D and tachysterol (Holick 
and Garabedian, 2006). Once vitamin D was completely purified, the researchers 
called it vitamin D2, which can be found in fungi, plants and yeast. This is 
distinguished from the later purified vitamin D3 which is endogenous to animals, 
including humans. Vitamin D2 is molecularly distinguished from vitamin D3 by its 
side chain (Figure 1), which contains a double bond between carbons 22 and 23 
as well as a methyl group on carbon 24 (Holick et al, 1989).  
 
Figure 1: Structures for 7-dehydrocholesterol (7-DHC), vitamin D3, ergosterol, and vitamin D2 
(Holick et al, 1981). 
Vitamin D Metabolism  
In animals, endogenous production of vitamin D3 occurs in the 
keratinocytes of the epidermis and dermis. Of the five strata or layers comprising 
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the epidermis, the precursor to vitamin D3, provitamin D3 or 7-dehydrocholesterol 
(7-DHC), is most prevalent in the stratum spinosum and stratum basale (Holick et 
al, 1980), where it resides in the plasma membrane and absorbs the energy from 
solar ultraviolet B (UVB, 315-280 nm) irradiation (Figure 2).  UVB causes the 7-
DHC molecule to open the B ring between carbons 9 and 10, producing 
previtamin D3.  Thermodynamically unstable, previtamin D3 quickly isomerizes to 
vitamin D3 (cholecalciferol). However, unlike 7-DHC and previtamin D3, vitamin D 
is not planar; therefore, vitamin D3 cannot remain in plasma membrane and is 
expelled into the extracellular space between keratinocytes (Tian et al, 1993; 
Tian and Holick, 1995). The presence of vitamin D binding protein (DBP) in the 
blood draws vitamin D3 to the circulation along its concentration gradient, 
allowing continual production of vitamin D3 long after initial UVB irradiation 
(Haddad et al, 1993). 
 
Figure 2: Synthesis, activation and catabolism of vitamin D3 (Dusso et al, 2005). 
 Though previtamin D3 isomerizes to vitamin D quickly and vitamin D exits 
the plasma membrane soon after, both can receive further UVB radiation. This 
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results in photoproducts: lumisterol and tachysterol, and lesser concentrations of 
suprasterols (Chen et al, 2000).   
 Vitamin D can also be obtained from the diet. Though available in two 
forms, vitamin D2 and vitamin D3, both are processed and activated in the same 
manner (Biancuzzo et al, 2010). Dietary vitamin D is absorbed from the gut 
primarily in the duodenum (Holick, 2000) and then is transported in the lymph on 
chylomicrons. After the chylomicrons enter circulation through the superior vena 
cava, vitamin D slowly transfers to DBP (Jones, 2008).  
 As a lipophilic molecule, vitamin D requires a binding protein for transport 
in the blood. A small percentage of vitamin D is bound to albumin, but the 
majority is bound to vitamin D binding protein (DBP). DBP binds vitamin D with a 
relatively low affinity, and vitamin D has a half-life of ~ 24 hours in the 
bloodstream (Jones, 2008). Regardless of the source, vitamin D requires two 
hydroxylations in the liver then kidney to reach its active form.  
The first reaction occurs in the liver by 25-hydroxylase (25-OHase), a 
cytochrome P450 enzyme encoded by the CYP27A1 gene (Cheng et al, 2004). 
The resulting in 25-hydroxyvitamin D (25(OH)D) is the major circulating form of 
vitamin D and indicator of vitamin D status. Both forms of 25(OH)D, 25(OH)D3 
and 25(OH)D2, have a magnitude of affinity for DBP higher than their precursors, 
resulting in half lives of ~15 days in circulation (Jones, 2008).  
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Figure 3: Uptake and activation of 25-hydroxyvitamin D in renal proximal tubular cells by megalin-
mediated endocytosis. After being filtered by the kidney, the 25(OH)D-DBP complex is removed 
from the lumen by megalin-mediated endocytosis. The complex dissociates, and degradation of 
DBP in the lysosome occurs. The 25(OH)D reaches the mitochondria and is hydroxylated by 
1alpha-hydroxylase to form 1,25(OH)2D, which exits the cell and is bound by DBP in the 
bloodstream. Alternatively, 25(OH)D can reenter the circulation and bind DBP again (Dusso et al, 
2005). 
Upon reaching the kidney, renal tubule cells take up the DBP-25(OH)D 
complex through megalin-mediated endocytosis (Nykjaer et al, 1999), seen in 
Figure 3. There, in the rate-limiting step of vitamin D3 activation, 25(OH)D-1α-
hydroxylase (1α-OHase), another cytochrome P450 and coded by CYP27B1 
(Rowling et al, 2007), adds a second hydroxyl group to 25(OH)D, resulting in the 
active 1,25-dihydroxyvitamin D (1,25(OH)2D; calcitriol). 1,25(OH)2D3 circulates 
loosely bound to DBP until it reaches target cells where it enters, binds to the 
vitamin D receptor (VDR) in the nucleus, and alters gene expression. However, 
the active 1,25(OH)2D has a very short half-life of only 4 hours in blood (Jones, 
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2008). This may be due to the fact that 1,25(OH)2D has the least affinity for DBP, 
resulting in easy displacement by its precursors as their levels rise (Jones, 2008).   
Regulation of Vitamin D 
Vitamin D’s most crucial role in vertebrates is calcium homeostasis by 
increasing intestinal absorption of dietary calcium. Sufficient 25(OH)D 
concentrations enable absorption of 30% of dietary calcium and 80% of dietary 
phosphorus (Deluca, 2004; Heaney et al, 2003). Specifically, 1,25(OH)2D 
increases the calcium absorptive efficiency of the small intestine, as well as 
elevating reuptake of calcium in the kidneys. Multiple factors tightly control the 
conversion of 25(OH)D to its active form, including parathyroid hormone (PTH), 
serum phosphorus and serum calcium levels (Deluca, 2004). In contrast, 
fibroblast growth-factor 23 (FGF-23) suppresses 1,25(OH)2D production (Hruska, 
2006). 1,25(OH)2D also increases the expression of 25-hydroxyvitamin D-24-
hydroxylase (CYP24), which degrades 1,25(OH)2D into calcitroic acid, a 
biologically inactive and water-soluble product that can be excreted (Hruska, 
2006). 25(OH)D follows a similar degradation pathway and is hydroxylated at 
position 24, resulting in 24,25(OH)2D (Deluca, 2004).  
Non-Calcemic Effects of Vitamin D 
Vitamin D has numerous physiological functions, including effects on the 
immune system, cardiac system, and metabolism (Figure 4).  Evidence showing 
the presence of vitamin D receptor and active 1,25(OH)2D in most tissues in the 
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body, including the brain, colon, breast tissues as well as immune cells, strongly 
supports these suppositions (Stumpf et al, 1979; Chen et al, 2000). 1,25(OH)2D 
interacts with VDR to directly or indirectly modulate the expression of more than 
200 genes, including those in the crucial pathways of differentiation, apoptosis, 
and proliferation (Nagpal et al, 2005).  
 
Figure 4: Vitamin D has effects on many important physiological functions (Holick, 2004). 
Work done by Tanaka et al gave the first insight into the presence of VDR 
in so many cell types unrelated to calcium metabolism: inhibition of proliferation 
(Tanaka et al, 1982). After incubating VDR-containing mouse and human 
leukemic cells with 1,25(OH)2D3, proliferation was inhibited and differentiation 
was stimulated. Numerous subsequent in vitro studies corroborated the anti-
proliferative property of 1,25(OH)2D3 on cell lines positive for VDR. To take this 
theory into the clinic, Smith et al applied topical 1,25(OH)2D3 to patients with 
severe psoriasis, a hyperproliferative disorder of VDR-positive keratinocytes, and 
observed significant, dose-dependent resolution of symptoms (Smith et al, 1988). 
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Since this revolutionary discovery in 1988, topical 1,25(OH)2D and analogues are 
considered the first-line treatment for psoriasis and are available around the 
world (Holick, 2004).  
The presence of 1α-OHase in extrarenal cells is also a strong indicator of 
the non-calcemic effects of vitamin D. Production of 1,25(OH)2D in these cells 
serves an autocrine or paracrine function (Holick, 2002).  
Vitamin D Deficiency 
Humans require adequate circulating 25(OH)D levels for the tightly 
regulated calcium homeostasis as well as overall health. Vitamin D deficiency is 
a worldwide epidemic; an estimated one billion individuals are vitamin D 
insufficient or deficient (Holick, 2004; Holick, 2007; O’Shea, 1998; Dawson-
Hughes, 2005). In children, vitamin D deficiency manifests as rickets; in adults, 
vitamin D deficiency causes osteomalacia (Holick and Chen, 2008). Both 
diseases result from the need to maintain serum calcium by pulling the ion from 
mineralized bone.  
When lacking sufficient vitamin D, only 10 to 15% of dietary calcium can 
be absorbed (Holick and Garabedian, 2006; Deluca, 2004). If the body cannot 
maintain its serum calcium levels by dietary intake, it must find another source: 
bone. In both adults and children, vitamin D deficiency causes elevated PTH that 
enhances renal reabsorption of calcium, production of 1,25(OH)2D, as well as 
activating bone breakdown. This is achieved through stimulation of osteoblasts 
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by 1,25(OH)2D and PTH, transforming preosteoclasts to active, mature 
osteoclasts (Holick and Garabedian, 2006). By secreting hydrochloric acid, 
osteoclasts dissolve the collagen matrix in bone to retrieve stored calcium 
(Hruska, 2006; Heaney et al, 2003; Sahota et al, 2006). Additionally, the elevated 
PTH reduces phosphorus reuptake in the kidney, which leads to an insufficient 
calcium x phosphorus product that prohibits proper mineralization of bone, 
leaving only the jelly-like collagen matrix and further increasing risk of 
osteopenia, osteoporosis and fracture (Holick, 2004).  
25(OH)D is the major form of vitamin D in the blood and circulates at a 
concentration one thousand times higher (ng/ml) than the active 1,25(OH)2D 
(pg/ml).  Moreover, 1,25(OH)2D concentrations are tightly regulated, even in a 
vitamin D deficient state (Holick, 2004).  Therefore, measuring 25(OH)D is the 
most useful diagnostic tool for vitamin D deficiency. Experts in the field have 
divided vitamin D status into sufficient, insufficient and deficient. Though 
definitions can vary, vitamin D sufficiency is generally regarded as greater than 
30 ng/ml (75 nmol/L) (Oshea, 1998), insufficiency ranges between 20 to 29 ng/ml 
(45-74 nmol/L), and deficiency encompasses any values below 20 ng/ml (45 
nmol/L) (Dawson-Hughes, 2005). Intoxication by vitamin D occurs when serum 
25(OH)D levels rise over 150 ng/ml (374 nmol/L) (Jones, 2008).  
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Vitamin D Deficiency: A Historical Perspective 
 
Figure 5: Typical presentation of children with rickets. The middle child is normal; the children on 
both sides have rickets presenting with severe muscle weakness and bone deformities, including 
knock knees (left) and bowed legs (right) (Holick, 2004). 
The sun has been appreciated for its warmth and light, as well as its life-
giving properties, for eons. However, evidence supporting the latter was only 
realized when the Industrial Revolution dramatically changed cities in Europe and 
the United States. Instead of spending a significant amount of time in the sun, 
people began working inside factories and living in cities with tall, closely 
constructed buildings that blocked direct sunlight. Furthermore, the use of coal in 
factories clogged the atmosphere, further limiting the amount of direct sunlight 
that could reach city streets. These limitations in access to sunlight resulted in a 
sharp increase in growth retardation and skeletal deformities.  The latter, shown 
in Figure 5, including bony projections along the rib cage (rachitic rosary) and 
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either knocked knees or bowed legs, are classic manifestations of the 
devastating pediatric disease called rickets (Holick, 2007).  
Doctors struggled to treat children with rickets and local therapies began 
appearing. On the coasts of Britain, cod liver oil was given to children to prevent 
and treat rickets. In 1918, Mellanby et al. showed that rickets could be stymied in 
dogs by feeding them cod liver oil (Holick, 1989). One year later, a German 
physician named Huldschinsky discovered using a mercury vapor arc lamp on 
patients could also prevent and cure rickets (Deluca, 2004). These findings led 
researchers to study substances with anti-rachitic properties. In 1925, Hess et al 
determined that when cholesterol was exposed to irradiation, an anti-rachitic 
byproduct resulted (Hess et al, 1925). In 1928, the chemical structures of both 7-
DHC and vitamin D3 were determined (Gloth, 1991). This revolutionary early 
research eventually led to the isolation, purification and identification of the anti-
rachitic vitamin D. Fortification of this substance in milk and other foods virtually 
eradicated rickets as a significant health issue for growing children in 
industrialized cities (Holick, 1989) 
 Vitamin D deficiency manifests more subtly in adults.  Osteomalacia 
presents in the clinic as aching bones, as well as muscle discomfort and 
weakness (Holick, 2004; Gloth et al, 1991). The isolated or general pain is due to 
hydration of the poorly mineralized matrix, which puts pressure on the highly 
innervated periosteum (Holick, 2006). These patients are often misdiagnosed 
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with fibromyalgia, depression, or chronic fatigue syndrome (Plotnikoff and 
Quigley, 2003). Evidence suggests that 40-60% of patients diagnosed with 
fibromyalgia may instead be vitamin D deficient, causing osteomalacia (Holick, 
2004). Diagnosis of osteomalacia can be accomplished by eliciting pain through 
pressing on a patient’s anterior tibia or sternum (Holick, 2006).   
Beneficial Actions of Vitamin D 
Exposure to sunlight is the principle source of vitamin D. In 1941, the 
direct correlation between incidence of cancer and latitude in the USA was first 
demonstrated by Dr. Apperly (Apperly, 1941). Though Apperly was ignored until 
the 1980s, his research was validated when both colon and breast cancer risks 
were similarly correlated to increased latitude (Holick, 2004). Since then, a 
plethora of studies have shown that disease incidence and associated mortality 
are significantly higher in people raised further from the equator, specifically 35 
degrees N. As the cutaneous production of vitamin D is more efficient at lower 
latitudes, vitamin D status might be the link (Webb et al, 1988). This has been 
supported by mounting evidence suggesting that elevating vitamin D status by 
increasing intake of vitamin D decreases the risks of developing chronic diseases 
(Holick, 2004). This is especially important in winter months in high-risk latitudes, 
where the zenith angle of the sun prevents penetration of UVB radiation through 
the ozone, completely inhibiting all significant cutaneous production of vitamin D.  
Webb et al provided evidence for this by showing that winter sunlight in Boston 
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does not produce significant vitamin D synthesis (Webb et al, 1988). They also 
showed that, even in the summer, only sunlight between the hours of 10 AM and 
3 PM is sufficient to prompt vitamin D production (Webb et al, 1988).  
Sources of Dietary Vitamin D 
 One reason for the epidemic of vitamin D deficiency is its low natural 
occurrence in common foods. The only foods that contain large quantities of 
vitamin D are oily fish and UVB-exposed mushrooms. The most significant 
quantities are found in fatty fish (100-500 IU of vitamin D3 per serving), such as 
salmon, herring, mackerel and sardines (Grant and Holick, 2005). Evidence 
shows that wild caught fish have higher, if more variable, vitamin D3 content 
when compared to farmed fish (Lu et al, 2007).  
Fortification of foods with vitamin D is a common practice, though 
determination of their bioavailability is more elusive. Dairy products are often 
fortified with vitamin D. Milk naturally has very small amounts of vitamin D, but 
not enough for a growing baby, requiring a breast feeding mother to supplement 
their diet (Holick, 2000). Fortified milk generally contains 400-600 IU per quart 
(Grant and Holick, 2005), translating to 100 IU/cup (Tangpricha et al, 2003). 
However, previous studies (Holden and Lemar, 2008) showed that 10 to 15% of 
milk have no detectable levels of vitamin D, indicating a flaw in the fortification 
system that must be addressed. In 2010, Patterson et al determined that the 
average vitamin D3 content of milk in the USA was just over the declared 
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fortification level of 400 IU/quart, though some samples still had undetectable 
levels (Patterson et al, 2010). Eggs have vitamin D in the yolk, and levels can be 
increased by elevating the amount of vitamin D in hen’s feed. Margarine is often 
fortified to varying levels regulated by country (Liu, 2012).  
Recent studies have shown that vitamin D in orange juice is just as 
bioavailable as supplementation (Biancuzzo et al, 2010; Tangpricha et al, 2003). 
Tangpricha et al first demonstrated the bioavailability of orange juice fortified with 
vitamin D in 2003 (Tangpricha et al, 2003). This study established that, although 
vitamin D is fat-soluble, consuming fortified orange juice was an acceptable 
method of vitamin D consumption (Tangpricha et al, 2003). In 2010, Biancuzzo et 
al determined that orange juice fortified with 1000 IU of either vitamin D2 or D3 
were equally effective at raising 25(OH)D levels as capsules containing 
equivalent amounts (Biancuzzo et al, 2010). 
Unfortunately, an outbreak of vitamin D intoxication in 1950 led to a public 
fear of vitamin D overdose and enactment of laws in Europe that forbade vitamin 
D fortification. Though this is still in effect, some cereals are now fortified (Jones, 
2008), though Norway does not allow fortification of foods with vitamin D (Calvo 
et al, 2005). 
Mushrooms as a Source of Vitamin D 
 For centuries, mushrooms have been lauded for their medicinal value. 
Recently, studies have shown that, when irradiated with UVB, the fungi produce 
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substantial quantities of vitamin D2 and sometimes even vitamin D4 because they 
contain a great deal of ergosterol (Urbain et al, 2011). Animal (Jasinge et al, 
2005; Calvo et al, 2013; Xu et al, 2013; Babu et al, 2014) and clinical studies 
(Urbain et al, 2011; Keegan et al, 2012; Stephensen et al, 2012) testing the 
bioavailability of vitamin D2 supplementation via irradiated mushrooms have 
shown increases in circulating 25(OH)D. Urbain et al demonstrated that just two 
weeks of supplementation with irradiated white button mushrooms containing 
28,000 IU of vitamin D2 had increases in vitamin D status comparable to those 
taking supplemental vitamin D2 capsules (Urbain et al, 2011). Keegan et al 
determined that the bioavailability of vitamin D from mushrooms compared to 
supplemental D2 and D3 were comparable in increasing serum 25(OH)D levels 
(Keegan et al, 2012).  
 Establishing irradiated mushrooms as a source of vitamin D is significant 
because of several factors. Aside from providing another reliable source of 
vitamin D, individuals that avoid certain products or preparation methods, such as 
vegetarians and vegans, can consume irradiated mushrooms, while vitamin D2 
obtained from yeast and vitamin D3 acquired from lanolin might not be an option.  
Vitamin D Supplements 
To avoid vitamin D deficiency, patients must take vitamin D supplements 
because they cannot rely on photoproduction or dietary intake, especially during 
the winter.  Though the Institute of Medicine (IOM) improved their 
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recommendations in 2010 for patients aged 3 to 70 years old to 600 IU/day, with 
a maximum safe upper limit of 4,000 IU/day (Ross et al, 2011), rising evidence 
suggests that this is insufficient and will not change a deficient patient’s vitamin D 
status enough to become sufficient (Lenders et al, 2009). The IOM advises that 
those older than 70 years of age consume 800 IU/day (Ross et al, 2011). 
However, the Endocrine Society recommends that healthy adults of all ages have 
a daily intake of 1500 to 2000 IU of vitamin D, increasing that value if they have 
low sun exposure (Holick et al, 2011). The upper limit for adults listed by the 
Endocrine Society is 10,000 IU/day, significantly higher than the IOM (Holick et 
al, 2011). Pludowski et al published guidelines for vitamin D supplementation in 
Central Europe, recommending 800 to 2000 IU/day, depending on body weight 
(Pludowski et al, 2012). Due to vitamin D’s lipophilicity, vitamin D can accumulate 
in body fat compartments. Therefore, decreased bioavailability has been 
observed in obese individuals, requiring them to double or triple their vitamin D 
intake to avoid becoming deficient (Wortsman et al, 2000; Lenders et al, 2009). 
Furthermore, 50,000 IU of vitamin D2, to be taken once every two weeks, is 
regularly prescribed and shown to be safe for up to six years (Pietras et al, 2009). 
Commercially, only vitamin D2 is available as a pharmacological 
preparation because its use predated the FDA. Vitamin D2 is generated by 
extracting ergosterol from yeast and irradiating with UVB. Although commercially 
developed in the 1950s, vitamin D3 has not been approved by the FDA. Even so, 
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vitamin D3 is used in food supplementation and vitamin supplements, and is 
made by obtaining lanolin from sheep wool, of which 7-DHC is a component, and 
irradiating with UVB (Holick et al, 2008).  
Vitamin D and the Immune System 
 Research has demonstrated the crucial role of vitamin D in the immune 
system. Vitamin D sufficiency improves epithelial barrier function, immune 
modulation and the production of antimicrobial peptides, such as cathelicidin 
(Schwalfenberg, 2011). Additionally, latitude and UVB exposure have been 
correlated with multiple sclerosis and other autoimmune disorders (Holick, 2004). 
1,25(OH)2D is a potent immunomodulator. This is exemplified in the response of 
monocytes and macrophages to Mycobacterium tuberculosis, which increases 
expression of VDR and 1α-OHase. The elevated 1,25(OH)2D causes synthesis of 
cathelicidin, an antimicrobial peptide that can eradicate M. tuberculosis and other 
infectious diseases (Holick, 2007). Furthermore, local infection or injury to most 
epithelial tissue results in increased expression of cathelicidin (Schwalfenberg, 
2011). Additionally, 1,25(OH)2D can suppress the inflammatory response, 
effectively preventing further damage by inhibiting expression of pro-inflammatory 
cytokines (Schwalfenberg, 2011). Major mechanisms of vitamin D-mediated 
immunomodulation are shown in Figure 6. 
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Figure 6: Mechanisms of vitamin D immunomodulation. Both systemic and locally produced 
1,25(OH)D3 can influence multiple immune cell types, including monocytes and macrophages, 
dendritic cells (DCs), effector T cells, and B cells. Macrophages and DCs constitutively express 
VDR, while T cells upregulate VDR expression only following activation. In macrophages and 
monocytes, active vitamin D3 positively stimulates its own effects by increasing the expression of 
CYP27B1 and VDR. Additionally, certain toll-like-receptor (TLR)-mediated signals also increase 
expression of VDR. 1,25(OH)2D3 also induces monocyte proliferation and the expression of 
cathelicidin and interleukin-1 (IL-1) by macrophages, contributing to the innate immune response 
to some bacteria. In T cells, 1,25(OH)2D3 decreases production of cytokines and attenuates the 
cytotoxic activity and proliferation of CD4+ and CD8+ T cells. Lastly, 1,25(OH)2D3 blocks B-cell 
proliferation, plasma cell differentiation and immunoglobulin production (VD3: vitamin D3; Mora et 
al, 2008).  
 In addition to responding to vitamin D, immune cells express both 25-
OHase and 1α-OHase, allowing local activation of vitamin D and subsequent 
autocrine and paracrine action (Figure 7). Expression of these enzymes varies 
among different kinds of immune cells, strongly indicating the importance of local 
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production of 1,25(OH)2D among specific populations of immune cells (Mora et 
al, 2008).  
 
Figure 7: Overview of vitamin D metabolism, activation, and interaction with immune cells.  
Immune cells, including macrophages, dendritic cells (DCs), T and B cells, express the enzymes 
CYP27A1 (25-OHase) and/or CYP27B1 (1α-OHase). Expression of these enzymes allows 
hydroxylation of vitamin D to its active form, 1,25(OH)D3, which acts on immune cells in an 
autocrine or paracrine manner by binding to VDR. CYP24A1 (24-hydroxylase) catabolizes 
1,25(OH)2D3 to calcitroic acid, which is excreted in the bile (VD3: vitamin D; Mora et al, 2008). 
Vitamin D and Genomics 
 Studies utilizing cultured human cells to generate in vitro microarray data 
have helped illuminate the molecular genetic basis for the diverse effects of 
1,25(OH)2D (Tarroni et al, 2012; Wang et al, 2005). Broad microarray analysis of 
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osteoblasts treated with 1,25(OH)2D3 showed the importance of 1,25(OH)2D3 in 
crucial regulatory and metabolic pathways (Tarroni et al, 2012). Using an 
immortalized prostate epithelial cell line, Kovalenko et al demonstrated that 
1,25(OH)2D elicited a strong, coordinated regulatory pattern of gene expression 
that limits carcinogenesis (Kovalenko et al, 2010).   
In 2013, Carlberg et al proposed two transcriptomic biomarkers, CD14 and 
thrombomodulin (THBD), for vitamin D signaling in both peripheral white blood 
cells and adipose tissue (Carlberg et al, 2013). Upregulation of CD14 and THBD 
had positive correlations with elevated 25(OH)D3 concentrations, which could 
potentially establish CD14 and THBD as personalized indicators of the 
effectiveness vitamin D3 supplementation (Carlberg et al, 2013). 
 In 2013, Hossein-nezhad et al demonstrated the influence of vitamin D 
status and supplementation on broad gene expression in white blood cells 
(Hossein-nezhad et al, 2013). In a randomized, double-blind clinical trial, eight 
subjects were treated with either 400 IU or 2000 IU of vitamin D3 for two months, 
and broad gene expression was tested by microarray before and after treatment. 
As seen in Figure 8, Hossein-nezhad et al found that almost 300 genes involved 
in pathways linked to autoimmune disorders, cancer and cardiovascular disease, 
were significantly altered by improving the subjects’ vitamin D status (Hossein-
nezhad et al, 2013). 
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Figure 8: Heatmap of vitamin D responsive genes affected by vitamin D status. Before 
supplementation (light green), four subjects were vitamin D deficient with 25(OH)D of 16.2 ± 4.2 
(dark purple) and the other four subjects were insufficient or sufficient with 25(OH)D of 27.5 ±  8.4 
(light purple). After supplementation (dark green), serum levels of 25(OH)D in vitamin D deficient 
subjects increased to 25(OH)D of 25.1 ± 4.7 ng/ml (dark purple) and the insufficient/sufficient 
subjects increased to 35.2 ± 8.2 ng/ml (light purple). Two groups of gene expression are seen 
based on stimulation (brown) or inhibition (blue) post vitamin D3 supplementation. High 
expression (brown), average expression (white) and low expression (blue) indicate the degree of 
gene expression (Hossein-nezhad et al, 2013).   
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Consistent with more recent observations (Carlberg et al, 2013), Hossein-
nehzhad et al found strong upregulation of CD14 and THBD across all subjects. 
However, Carlberg et al demonstrated that, of the five genes selected by 
Hossein-nezhad as representative markers (Hossein-nezhad et al, 2013), only 
the KLF10 gene has a VDR binding site in colon cancer cells (Carlberg et al, 
2013). 
The purpose of this thesis is to determine the changes in broad gene 
expression in human white blood cells in response to vitamin D supplementation, 
specifically in healthy adults taking mushroom powder, vitamin D2 in irradiated 
mushroom powder, supplemental vitamin D2, or supplemental vitamin D3.  This 
work will also determine the reproducibility of the preliminary study by Hossein-
nezhad et al, and expand the subject size to hopefully determine more details 
regarding the molecular mechanisms underlying the non-calcemic health benefits 
of vitamin D sufficiency.  
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METHODS 
 
Trial Design 
 This study was a randomized, controlled, double-blind, investigator-
initiated, single center pilot trial. A total of 75 subjects were recruited and 
randomly assigned to groups to receive vitamin D supplementation. Demographic 
information is summarized in Table 1. To minimize sun exposure as a 
confounding factor, the study was conducted in the winter months of 2012 and 
2013. Of this larger subject pool, subjects had to meet certain criteria for 
inclusion in the broad gene expression part of the study, including demonstrated 
compliance via weekly 25(OH)D blood tests and a starting insufficient or deficient 
25(OH)D status (less than 30 ng/ml) with lower vitamin D statuses preferable.  
Characteristics  MP Mushroom D2  D2 D3 
Age (n) (5) (15) (11) (9) 
     Mean ± SD (years) 23.8 ± 1.5 28.8 ± 11.4  32.4 ± 11.6  32.4 ± 14.0  
     Range (years) 22 – 26  21 - 67 22 - 57  23 - 63 
Female (%) 2 (40.0) 10 (66.6) 7 (63.6) 5 (55.6) 
Male (%) 3 (60.0) 5 (33.3) 4 (36.4) 4 (44.4) 
Body mass index in kg/m2 (n) 24.6 ± 2.6 (5) 22.6 ± 2.1 (14) 24.8 ± 4.2 (7) 23.7 ± 4.6 (8) 
Table 1: Demographic information compiled from both halves of the study (MP: mushroom 
powder; SD: standard deviation). 
 Subjects received supplement capsules containing 2000 IU vitamin D or a 
placebo. Supplemental vitamin D2 and supplemental vitamin D3 are the variants 
found in common supplements. Nature’s Life (Park City, UT) provided the vitamin 
D2 capsules and Whole Health (Golden, CO) provided vegetarian vitamin D3 
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capsules. Mushroom vitamin D2 (MD2) was obtained by irradiating 0.4g white 
button mushroom powder with UVB (Monterey Mushrooms, Inc, Watsonville, 
CA). In the second half of the study, the added placebo group capsule (MP) 
contained 0.4 g of mushroom powder that was not irradiated and was also 
provided by Monterey Mushrooms, Inc. HPLC analysis of the capsules’ content 
was performed and is summarized in Table 2.   
  D2 (IU/capsule) D3 (IU/capsule) 
Mushroom powder ND ND 
Mushroom D2 2938 ± 91 ND 
Supplemental D2 2325 ± 203 ND 
Supplemental D3 ND 2547 ± 183 
Table 2: Vitamin D content in capsule supplements (ND – not detectable). 
In the first half of the study, thirty healthy adults were enrolled in the study 
and were randomly assigned to three groups to receive capsules containing 2000 
IU/d of mushroom vitamin D2, supplemental vitamin D2, or supplemental vitamin 
D3 for thirteen weeks during the winter of 2012. 20 subjects (5 male, 15 female; 
mean age 34.7 y) met study criteria, and 10 subjects were randomized to the 
mushroom vitamin D2 group, 6 subjects to the supplemental vitamin D2 group and 
4 subjects to the supplemental D3 group.  
For the second half of the study, a placebo mushroom powder capsule 
was introduced, resulting in four groups instead of three. Forty-five healthy adults 
were recruited and enrolled in the winter of 2013 and were randomized to ingest 
capsules containing placebo mushroom powder or 2000 IU of mushroom vitamin 
D2, supplemental vitamin D2, or supplemental vitamin D3. 20 subjects (11 male, 9 
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female; mean age 25.3 y) were eligible for gene expression analysis in the 
second half of the study, and 5 subjects were randomized to the placebo 
mushroom powder group, 5 subjects to the mushroom vitamin D2 group, 5 
subjects to the supplemental D2 group, and 5 subjects to the supplemental D3 
group.  
This resulted in a total of 40 subjects (16 male, 24 female, mean age 30.0 
y) included in the study, with 5 subjects randomized to the mushroom powder 
group, 15 subjects to the mushroom D2 group, 11 subjects to the supplemental 
D2 group, and 9 subjects to the supplemental D3 group. This subset of the 
original 75 subjects is described in this report.  
 Serum concentrations of 25(OH)D2 and 25(OH)D3 were measured once a 
week for twelve weeks by liquid chromatography tandem mass spectroscopy 
(LCMS/MS) as previously described (Hermann et al, 2010). Total 25(OH)D was 
determined by adding those values. Buffy coats were obtained from blood 
samples drawn at 0 and 12 weeks from all subjects who qualified for broad gene 
expression analysis.  
 Aside from the addition of the group receiving mushroom powder, two key 
variations occurred in processing the samples from the first and second half of 
the study. In the first half of the study, a density media gradient of 1.077 g/ml 
(Ficoll-Paque, Sigma-Aldrich, St. Louis, MO) was used to obtain the buffy coat 
(white blood cells) from whole blood, while a density media gradient of 1.085 g/ml 
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(RosetteSep, Vancouver, BC) was used in the second half of the study. This was 
not realized until after collection of samples was completed and could potentially 
result in a different population of cells i.e. loss of smaller white blood cells, such 
as lymphocytes. There is a possibility that this change in ratio or population of 
white blood cells could result in differing broad gene expression profiles. 
In addition, use of the second density media gradient led to a significant 
quantity of blood cells accompanying the buffy coat, resulting in a pink coloration. 
This led to complications in extracting RNA, necessitating the use of Trizol of 
over just a Qiagen RNA Isolation kit.  
Secondly, buffy coats from the first half of the study were stored in 
differing buffers to protect RNA from degradation, namely by inhibiting RNases, 
while stored at -80 degrees Celsius. QIAgen’s CellProtect, while samples from 
the second half were stored in QIAgen’s RNAlater. CellProtect is meant for cells, 
for example those grown in culture, while RNAlater is used for tissue samples. 
However, as blood and white blood cells can be considered both, this variance 
should not influence the integrity of the RNA, though it also could influence 
patterns of broad gene expression. 
RNA Isolation 
 Extracting RNA from all samples was completed after the conclusion of 
the study. RNA extraction from RNAlater proved to be much more difficult than 
samples stored in CellProtect. The presence of red blood cells in the RNAlater-
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stored samples clogged the Qiagen AllPrep RNA column, resulting in incredibly 
low and poor RNA yields. To optimize the RNA extraction, the phenol-chloroform 
method was used to lyse and separate the RNA from the rest of the sample.  
Once separated into aqueous and organic phases, containing RNA and 
proteins/DNA respectively, the aqueous phase would be transferred to the 
Qiagen RNA column for further purification following their protocol. However, this 
was insufficient to acquire excellent quality RNA, so DNase treatment was added 
to the procedure. These changes, along with refining my technique and sterile 
practice as well as standardizing the protocol and reducing freeze/thaw cycles, 
resulted in high quality, pure RNA.  
Preparing Buffy Coat Samples 
After thawing samples in the 4°C refrigerator, the samples were 
centrifuged at 3000 g for five minutes at 4°C. With the cells pelleted, removal of 
the RNA-protecting buffer was accomplished with a pipette. Presence of 
CellProtect or RNAlater interfered with later reagents, so removing as much as 
possible without disturbing the pellet was an important step. Of note, the pellets 
from the first half, those stored in CellProtect, were very easily disturbed and had 
to be approached with more caution than those stored in RNAlater. Decanting the 
buffer for the latter to remove the majority of the RNAlater then proceeding with a 
pipette was acceptable.  
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Phenol-Chloroform Steps 
To lyse the pellet, 1 ml of Trizol (Isol-RNA, Prime) was used with vigorous 
pipetting and vortexing until no cellular debris could be observed. After allowing 
the Trizol mixture to stand at room temperature for ten minutes, 250 μl of 
chloroform was added, and the samples were vortexed again and then incubated 
at room temperature for two minutes.  The samples were then spun at 13,000 
RPM for twenty minutes at 4°C, separating the upper aqueous and bottom 
organic phases. After carefully removing the tubes to avoid disturbing the 
interphase of the layers, the aqueous phase was removed to a 2 ml Eppendorf 
tube using a 200 μl pipette, and the organic phase was stored at -20°C for later 
DNA isolation. If organic phase was accidentally added to the fresh tube, an 
additional spin of two minutes at 13,000 RPM and room temperature was done 
and the subsequent supernatant transferred to a fresh 2 ml tube. Next, 1.5 ml of 
cold (-20°C) 100% ethanol was added to precipitate the RNA.  
Qiagen Allprep Purification 
The ethanol-RNA mixture was then added, 700 μl at a time, to RNeasy 
spin columns (Qiagen, Valencia, CA). All short duration centrifugation were 
performed for thirty seconds at 10,400 RPM and room temperature. DNase was 
freshly prepared following Qiagen’s protocol and applied to the spin column for 
fifteen minutes. After spinning and discarding the flow through, two washes each 
of RW1 (700 μl, then 350 μl) and RPE (500 μl each time) were performed, 
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spinning and discarding the flow through each time. When care was taken to 
wash the sides of the column by inverting and spinning tubes with each buffer 
addition, higher quality RNA was obtained. Next, the spin column was dried by 
centrifuging for one minute at the same speed in a fresh collection tube, and then 
transferred to a 1.5 ml eppendorf. Then 55 μl of provided RNase-free water was 
applied to the spin column and allowed to incubate at room temperature for five 
minutes. Spinning for one minute then eluted the RNA. Finally, a 5 μl aliquot of 
each sample was transferred to a 0.5 ml tube and the tubes were stored at -80°C 
immediately.  The small aliquot was later used to determine RNA quality and 
concentration to avoid repeated freeze/thaw cycles. 
Determining RNA Quality and Concentration 
 After each RNA extraction, a small, 5 μl sample of RNA was transferred to 
a separate tube and the main 50 μl sample was immediately stored at -80 
degrees Celsius. This small sample was taken to the Microarray Core to be 
measured with their Nanodrop (Nanodrop 1000), giving concentration as well as 
an indication of each sample’s purity. Nanodrop uses spectrophotometry to 
measure the absorbance of a sample at wavelengths ranging from 200 to 360 
nm. Absorbance at 230, 260 and 280 nm are key when measuring nucleotide 
concentration and purity. More specifically, the ratios of 260/280 and 260/230 are 
of importance, with values between 1.9 and 2.1 indicating high quality.  
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 However, these ratios were insufficient to determine quality, and 
determining the samples’ RNA Integrity Number (RIN) by Bioanalyzer was 
necessary.  Therefore, the Microarray Core verified integrity and purity using 
RNA 6000 Pico Assay RNA chips run in Agilent 2100 Bioanalyzer (Agilent 
Technologies, Paolo Alta, CA). RIN values range from 1 to 10, with acceptable 
integrity and purity ranging from 7 to 10.  Plotting RIN versus 260/280 or 260/230 
by sample confirmed the necessity of determining RIN values. For several 
samples that had low RIN’s were re-extracted, resulting in comparable 
Bioanalyzer assay results and indicated general degradation of the whole 
sample.  
Microarray Sample Processing and Assay Preparation 
 The Microarray Core reverse transcribed the RNA using Whole Transcript 
cDNA Synthesis kit (Affymetrix, Santa Clara, CA) to generate antisense cRNA. 
The cRNA was purified using Genechip Sample Cleanup Module (Affymetrix, 
Santa Clara, CA) and used as a template for reverse transcription (Whole 
Transcript cDNA Synthesis kit, Santa Clara, CA) to produce single-stranded, 
sense DNA that incorporated dUTP. The cDNA was fragmented using uracil DNA 
glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE1), and 
labeled with DNA Labeling Reagent that is covalently linked to biotin using 
terminal deoxynucleotidyl transferase (TdT, Whole Transcript cDNA Synthesis 
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kit, Santa Clara, CA). cDNA and IVD fragmentation quality controls were 
confirmed by running an mRNA Pico assay in the Agilent 2100 Bioanalyzer.  
Statistical Analysis 
 Aside from analysis provided by the Microarray Core, all statistical 
analyses were performed using Microsoft Excel (2011) on a Macbook Pro.  
Raw Affymetrix CEL files were normalized to produce gene-level 
expression values using the implementation of the Robust Multiarray Average 
(RMA; Irizarry et al, 2003) in the affy package (version 1.36.1; Gautier et al, 
2004) included within the Bioconductor software suite (version 2.12; Gentleman 
et al, 2004) and Entrez Gene-specific probeset mapping (version 16.0.0) from the 
Molecular and Behavioral Neuroscience Institute (Brainarray) at the University of 
Michigan (Dai et al, 2003; Dai et al, 2005). Array quality was assessed by 
computing Relative Log Expression (RLE) and Normalized Unscaled Standard 
Error (NUSE) using the affyPLM Bioconductor package (version 1.34.0; Dai et al, 
2005). Principal Component Analysis (PCA) was performed using the prcomp R 
function with expression values that had been normalized across all samples to a 
mean of zero and a standard deviation of one. Analysis of variance on simple 
linear models was carried out using the f.pvalue function in the sva package 
(version 3.4.0). Paired t-tests were accomplished by performing Student’s t-test 
on the timepoint coefficient of a simple linear model treating expression as a 
function of subject and timepoint (equivalent of a paired Student’s t test) 
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computed using the lmFit function in the limma package (version 3.14.4; 
Brettschneider et al, 2008). Linear mixed-effects modeling and the associated 
analysis of variance were carried out using the lme and anova.lme functions, 
respectively, in the nlme package (version 3.1-108). Correction for multiple 
hypothesis testing was accomplished using the Benjamini-Hochberg false 
discovery rate (FDR; Smith, 2005). All microarray analyses were performed using 
the R environment for statistical computing (version 2.15.1; Benjamini and 
Hochberg, 1995; R Development Core Team, 2011).  
For Gene Set Enrichment Analysis (GSEA), the Entrez Gene identifiers of 
the human homologs of the genes interrogated by the array were ranked 
according to sign(βtimepoint)*sqrt(LRtimepoint), where LRtimepoint is the likelihood ratio 
of the timepoint term in a linear mixed-effects (LME) model that included 
timepoint as a fixed effect and subject as a random effect, and βtimepoint is the 
coefficient of the timepoint term in that model. This signed sqrt(LR) metric 
approximately follows a standard normal distribution (Barndorff-Nielsen et al, 
1994). Genes for which the LME model did not numerically converge were 
removed. Each ranked list was then used to perform a pre-ranked GSEA analysis 
(default parameters with random seed 1234) using the Entrez Gene versions of 
Biocarta, KEGG, Reactome, Gene Ontology (GO), and transcription factor and 
microRNA motif gene sets obtained from the Molecular Signatures Database 
(MSigDB), version 4.0 (Subramanian et al, 2007).   
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RESULTS 
 
Figure 9: Total 25(OH)D (blue), 25(OH)D2 (red) and 25(OH)D3 (green) responses to 
supplementation within each group. P values were calculated with a Student’s t test between 
initial and final values. (** p < 0.05; *** p < 0.01; n.s. not significant). 
Subjects in the mushroom powder group had a mean baseline serum total 
25(OH)D of 18.8 ± 4.1 ng/ml that did not significantly change at the end of the 
study, 20.6 ± 4.1 ng/ml (p = 0.10).  The mean baseline 25(OH)D2 did not 
significantly change from 0.8 ± 0.3 ng/ml to 0.6 ± 0.4 ng/ml (p = 0.26). The mean 
25(OH)D3 also did not change significantly from 18.0 ± 4.4 ng/ml to 20.0 ± 4.3 
ng/ml (p = 0.07).  
 Subjects in the supplemental mushroom D2 group had a mean baseline 
total 25(OH)D serum of 20.5 ± 8.1 ng/ml that increased significantly to 31.4 ± 
11.0 ng/ml at the end of twelve weeks (p < 0.001). The mean baseline 25(OH)D2 
Total 25(OH)D, 25(OH)D2 and 25(OH)D3 response to supplementation within 
each group, abbreviated Total, D2 and D3, respectively.!
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increased significantly from 0.8 ±1.1 ng/ml to 18.7 ± 8.0 ng/ml (p < 0.001). The 
25(OH)D3 decreased significantly from a baseline of 19.8 ± 8.3 ng/ml to 12.7 ± 
6.7 ng/ml (p < 0.001).  
 MP  Mushroom D2 D2 D3 
Number of subjects 5 15 11 9 
Mean initial 25(OH)D ± SD (ng/ml) 18.8 ± 4.1 20.5 ± 8.1 19.6 ± 7.1 19.0 ± 5.4 
Mean final 25(OH)D ± SD (ng/ml) 20.6 ± 4.1 31.4 ± 11.0 31.4 ± 7.4 40.7 ± 8.6 
     Mean difference ± SD 1.8 ± 1.8 10.9 ± 10.2 11.8 ± 7.4 21.7 ± 8.9 
Mean initial 25(OH)D2 ± SD (ng/ml) 0.8 ± 0.3 0.8 ± 1.1 1.7 ± 3.1 0.8 ± 0.9 
Mean final 25(OH)D2 ± SD (ng/ml) 0.6 ± 0.4 18.7 ± 8.0 13.9 ± 5.3 0.2 ± 0.3 
     Mean difference ± SD -0.2 ± 0.4 18 ± 7.9 12.1 ± 4.3 -0.7 ± 1.0 
Mean initial 25(OH)D3 ± SD (ng/ml) 18.0  ± 4.4 19.8 ± 8.3 17.9 ± 7.1 18.2 ± 5.3 
Mean final 25(OH)D3 ± SD (ng/ml) 20.0 ± 4.3 12.7 ± 6.7 17.5 ± 6.0 40.5 ± 8.8 
     Mean difference ± SD 2.0 ± 1.8 -7.1 ± 5.0 -0.4 ± 5.6 22.3 ± 8.9 
Table 3: Vitamin D responses compiled from both halves of the study (SD, standard deviation). 
 Subjects in the supplemental D2 group had a mean baseline total 25(OH)D 
serum of 19.6 ± 7.1 ng/ml, which increased significantly to 31.4 ± 7.4 ng/ml (p < 
0.001). The mean baseline 25(OH)D2 increased significantly from 1.7 ± 3.1 ng/ml 
to 13.9 ± 5.3 ng/ml (p < 0.001). The 25(OH)D3 did not differ significantly from a 
baseline of 17.9 ± 7.1 ng/ml to 17.5 ± 6.0 ng/ml (p = 0.42). 
Subjects in the supplemental vitamin D3 group had a mean baseline 
serum 25(OH)D3 of 18.2 ± 5.3 that increased significantly to 40.5 ± 8.8 ng/ml at 
the end of twelve weeks (p < 0.001). Total serum 25(OH)D levels significantly 
increased from 19.0 ± 5.4 ng/ml to 40.7 ± 8.6 ng/ml (p < 0.001). The disparity 
between 25(OH)D3 and total 25(OH)D is due to a small presence of 25(OH)D2 in 
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some subjects, 0.8 ± 0.9 ng/ml at baseline and 0.2 ± 0.3 ng/ml at the end of the 
study.  
 
 
Figure 10: Comparison of trends in serum 25(OH)D, 25(OH)D2, and 25(OH)D3 between groups 
(left) and boxplot of final total 25(OH)D, 25(OH)D2 and 25(OH)D3 (right; x-axis: ng/ml). Post-hoc 
analysis using Tukey method gave the following significances: (A) Final total 25(OH)D was 
significant between mushroom powder and D3, mushroom D2 and D3, and D2 and D3 (p < 0.05). 
(B) Final 25(OH)D2 was significant between mushroom powder and mushroom D2, mushroom 
powder and D2, mushroom D2 and D3, and D2 and D3 (p < 0.05). (C) Final 25(OH)D3 was 
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significant between mushroom powder and D3, mushroom D2 and D3, and D2 and D3 (p < 0.05). 
(MP: mushroom powder; MD2: mushroom D2; D2: supplemental D2; D3: supplemental D3). 
Baseline serum total 25(OH)D levels were not significantly different 
between groups; 18.8 ± 4.1, 20.5 ± 8.1, 19.6 ± 7.1 and 19.0 ± 5.4 ng/ml for the 
mushroom powder, mushroom D2, supplemental D2 and supplemental D3 groups 
respectively (p = 0.94). Serum 25(OH)D levels gradually increased until seven 
weeks, where they plateaued and stabilized for the remaining weeks of the study. 
At the end of twelve weeks, one-way ANOVA determined that the final total 
25(OH)D levels were statistically significant at 20.6 ± 4.1, 31.4 ± 11.0, 31.4 ± 7.4, 
and 40.7 ± 8.6 ng/ml for supplemental mushroom powder, mushroom D2, 
supplemental D2 and supplemental D3, respectively (Figure 11a). The 
significance between each group pairing as determined uding a post-hoc Tukey 
test is shown in Figure 10. The change in serum 25(OH)D, 25(OH)D2 and 
25(OH)D3 by treatment group is depicted in Figures 11 and 12.  
 
Figure 11: Change in serum total 25(OH)D (blue), 25(OH)D2 (red), and 25(OH)D3 (green) from 
baseline to the end of the study. 
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Figure 12: Boxplot of change in serum (A) total 25(OH)D, (B) 25(OH)D2 and (C) 25(OH)D3. A post 
hoc analysis using Tukey method determined significance. (A) Change in total 25(OH)D was 
significant between mushroom powder and D3, and mushroom D2 and D3 (p < 0.05). (B) Change 
in 25(OH)D2 was significant between all groups except mushroom powder and D3 (p < 0.05), as 
expected as neither group received vitamin D2 supplementation. (C) Change in 25(OH)D3 was 
significant between all groups except mushroom powder and D2 (p < 0.05), as expected since 
neither group received vitamin D3 supplementation. 
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Figure 13: Change from baseline in serum 25(OH)D (blue), 25(OH)D2 (red), and 25(OH)D3 
(green) at each time point within each group. (A) In the mushroom powder group, change from 
baseline to final total 25(OH)D (p = 0.05) and 25(OH)D3  (p < 0.05) had statistical significance, 
though 25(OH)D2 did not (p = 0.13). (B) The mushroom D2 treatment group had significance at 
total 25(OH)D, 25(OH)D2 and 25(OH)D3 (p < 0.01). (C) Total 25(OH)D and 25(OH)D2 increased 
significantly (p < 0.01) in the supplemental D2 treatment group, though 25(OH)D3 did not change 
significantly (p = 0.42). (D) In the D3 supplemental group, total 25(OH)D and 25(OH)D3 were 
strongly significant (p < 0.01), and 25(OH)D2 was significant (p < 0.05). P-values were calculated 
with a Student’s t test between baseline change and change from baseline at each time point (** 
p < 0.05; * p < 0.01). 
As expected due to the tight regulation of the production of 1,25(OH)2D, 
total 1,25(OH)2D values did not vary significantly across all groups (Figure 14). 
However, in both mushroom D2 (Figure 14B) and supplemental D2 (Figure 14C) 
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treatment groups, 1,25(OH)2D2 rose significantly and 1,25(OH)2D3 decreased 
significantly, following the groups’ trends as seen in 25(OH)D. Calcium is also 
tightly regulated, was not expected to vary significantly and showed no significant 
difference in any treatment group (Figure 15). Parathyroid hormone levels 
showed a slight decreasing trend with increased 25(OH)D status, though 
statistical significance was not evident. Neither creatinine nor albumin had 
variation in levels from initial to final measurements (Table 4, Figure 15).   
 MP MD2 D2 D3 
Mean initial serum calcium ± SD (mg/dl) 9.7 ± 0.3 9.6 ± 0.4 9.6 ± 0.4 9.4 ± 0.2 
Mean final serum calcium ± SD (mg/dl) 9.5 ± 0.2 9.5 ± 0.4 9.6 ± 0.5 9.5 ± 0.4 
     Mean difference ± SD -0.14 ± 0.4 -0.08 ± 0.4 -0.04 ± 0.4 0.11 ± 0.4 
Mean initial serum PTH ± SD (pg/ml) 18.4 ± 5.4 29.0 ± 9.4 24.9 ± 8.7 23.4 ± 9.5 
Mean final serum PTH ± SD (pg/ml) 17.3 ± 3.1 31.9 ± 18.5 29.7 ± 9.6 22.8 ± 7.0 
     Mean difference ± SD -1.2 ± 5.0 1.9 ± 17.7 4.8 ± 10.7 -0.55 ± 9.5 
Mean initial creatinine ± SD (mg/dl) 0.8 ± 0.1 0.8 ± 0.1 0.9 ± 0.2 0.8 ± 0.2 
Mean final creatinine ± SD (mg/dl) 0.8 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.8 ± 0.2 
     Mean difference ± SD 0.02 ± 0.1 0.04 ± 0.1 -0.02 ± 0.1 -0.04 ± 0.1 
Mean initial albumin ± SD (g/dl) 4.8 ± 0.2 4.7 ± 0.3 4.5 ± 0.4 4.5 ± 0.3 
Mean final albumin ± SD (g/dl) 4.8 ± 0.3 4.7 ± 0.3 4.5 ± 0.3 4.6 ± 0.3 
     Mean difference ± SD 0.02 ± 0.2 0.07 ± 0.3 -0.01 ± 0.3 0.11 ± 0.2 
Table 4: Mean initial and final serum calcium, PTH, creatinine and albumin. Reference ranges 
are: calcium, 8.6 to 10.2 mg/dl; parathyroid hormone (PTH), 8 to 51 pg/ml; creatinine, 0.5 to 1.4 
mg/dl; albumin, 3.6 to 5.1 g/dl. T-tests run between initial and final lab values and one-way 
ANOVAS run between groups showed no significance.  
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Figure 14: Total serum 1,25(OH)2D (blue), 1,25(OH)2D2 (red) and 1,25(OH)2D3 (green) in (A) 
mushroom powder, (B) mushroom D2, (C) supplemental D2 and (D) supplemental D3. P-values 
were calculated with a Student’s t test between initial and final values. (** p < 0.05; *** p < 0.01; 
n.s. not significant) 
 
Figure 15: Ratio of final/initial serum 25(OH)D concentrations to final/initial ratios of other 
measured factors. Serum calcium showed a very slight positive trend as 25(OH)D status 
increased, though the calculated correlation (0.13) was insignificant (A). PTH demonstrated a 
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negative trend as 25(OH)D levels increased, with correlation = -0.26 (B). Neither albumin (Alb; 
correlation = 0.14) or creatinine (Cr; correlation = 0.14) showed correlation as 25(OH)D levels 
increased. The coefficient of determination (R2) values range from 0 to 1, with 1 indicating that the 
model explains all variability of the data around its mean. 
Microarray Analysis 
Normalization and Quality Assessment 
The microarrays were normalized together using the Robust Multiarray 
Average (RMA) algorithm and a Chip Definition File (CDF) that maps the probes 
on the array to unique Entrez Gene identifiers. A resulting matrix is generated, 
where each column corresponds to a sample and each row is an Entrez Gene ID. 
The technical quality was assessed by two quality metrics: Normalized Unscaled 
Standard Error (NUSE) and Relative Log Expression (RLE). For each sample, 
medial NUSE values > 1.05 or RLA values > 0.1 are considered outside the usual 
limits, although RLE is the quality metric most strongly associated with technical 
quality.  All arrays had median NUSE and RLE values well within these limits.  
Positive Control Gene Expression 
 The expression of five constitutively expressed, Y-linked genes was 
assessed to estimate the dynamic range of the experiment. These genes 
(DDX3Y, KDM5D, RPS4Y1, USP9Y, and UTY) serve as strong positive and 
negative expression controls in males and females, respectively (Figure 16). The 
expression of these male-specific genes was bimodal, with levels that were either 
quite high (~7 to 9 log2 units) or quite low (~2 to 3 log2 units), which indicated 
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that this experiment had good dynamic range to detect these controls. As an 
additional control, the expression of the glutathione S-transferase (GSTM1) gene 
was checked, as its frequent deletion polymorphism in human populations is well 
known. GSTM1 expression was bimodal, either robust (~6 to 7 log2 units) or very 
low (~2 to 3 log2 units), verifying the good dynamic range of this experiment. . 
Furthermore, the pairs of samples from each subject were consistent for both Y-
linked and GSTM1 expression, coordinating with subjects’ gender, which 
indicated that samples were correctly annotated at all steps in this experiment. 
A B  
Figure 16: Heatmap of absolute (unscaled) expression of control genes. (A) First half of the study; 
(B) second half of the study. High expression (red) of the male specific genes DDX3Y, KDM5D, 
RPS4Y1, USP9Y and UTY indicate male, while no expression (blue) indicate female. 
Principal Component Analysis  
 Principal component analysis (PCA) is a mathematical transformation that 
collapses the variance between samples across a large set of variables (all 
19673 genes) into a much smaller set of variables called principal components 
(PCs). These “meta-variables” are arranged so that PC1 shows the most 
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variance in the data, followed by PC2, etc. PCA was performed across all 
samples using all genes, and plots were made of PC2 versus PC1 (Figure 18). 
Points were either circles (pre-treatment) or squares (post-treatment). A cloud of 
samples without outliers indicates similar technical quality across all samples. 
The points were then colored by provided variables, such as subject (Figure 18A 
and B), treatment group (Figure 17C and D), RIN (Figure 18), total 25(OH)D 
(Figure 19A and B), total 1,25(OH)2D (Figure 19C and D), sample collection date 
(Figure 20A and B), date RNA extracted (Figure 20C and D), etc., to examine the 
effect of variables on the samples’ technical quality. Strong distribution of 
samples by one of these variables indicates a variable-dependent technical effect 
present in the data.  
In the samples from the first half of the study, there did not appear to be 
any strong outliers (Figure 17A). Although one sample did separate from the 
others along PC1, it did not explain the large amount of variance in the 
experiment and the sample did not appear unusual with respect to quality 
metrics. PCA plots generated by shading samples by treatment group (Figure 
17C), total 25(OH)D status (Figure 20B), 25(OH)D2, 25(OH)D3, total 1,25(OH)2D 
(Figure 20C), parathyroid hormone (PTH) and RNA extraction date (Figure 19C) 
showed regular distribution, indicating that these variables did not effect technical 
quality.  
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A  B  
C  D  
Figure 17: PCA plots colored by subject in the first half (A) and second half (B) and, treatment 
group in the first half (C) and second half (D). X-axis: PC1 (29%); y-axis: PC2 (16%). 
A B  
Figure 18: PCA plot colored by RIN (RNA Integrity Number), (A) first half and (B) second half. X-
axis: PC1 (29%); y-axis: PC2 (16%). 
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A  B  
C  D  
Figure 19: PCA plots colored by sample collection date in (A) first half and (B) second half, and 
RNA extraction date in the (C) first half and (D) second half. X-axis: PC1 (29%); y-axis: PC2 
(28%). 
In the second half of the experiment, samples were strongly distributed by 
RIN along PC2 (Figure 17) and there was some clustering of samples with 
respect to subject (Figure 17B). Additionally, there may be a time-dependent 
technical effect present due to the distribution of sample collection dates along 
PC1 (Figure 18B). However, PCA plots generated by shading samples by 
treatment group (Figure 17D), total 25(OH)D (Figure 20B), 25(OH)D2, 25(OH)D3, 
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total 1,25(OH)2D (Figure 20D), parathyroid hormone (PTH), and RNA extraction 
date (Figure 19D) showed regular distribution, indicating that these variables did 
not effect technical quality, as seen in the first half of the study.  
A  B  
C  D  
Figure 20: PCA Plots colored by total 25(OH)D in the (A) first half and (B) second half, and total 
1,25(OH)2D in the (C) first half and (D) second half. X-axis: PC1 (29%); y-axis: PC2 (16%). 
Differential Expression Analysis 
First, a simple linear modeling approach was used to identify genes whose 
expression changes with respect to the interaction of time and treatment group 
(i.e. genes whose expression changes over time only in one treatment group).  
	  48 
This was accomplished using a simple linear model of the form [expression ~ 
timepoint + group + timepoint:group], where ‘~’ means ‘is a function of’ and ‘:’ 
indicates an interaction between two variables. A two-way analysis of variance 
(ANOVA) was then performed to obtain a p-value for the interaction term 
(timepoint:group) for each gene. Benjamini-Hochberg False Discovery Rate 
(FDR) correction was then applied to obtain FDR-corrected p-values (aka q-
values), which represent the probability that a given result is a false positive 
based on the distribution of all p-values on the array. Corrected/adjusted values, 
such as the FDR q, are the best measure of significance for a given test when 
many hypotheses (e.g. ~20,000 genes) are tested at once.  
 To identify genes whose expression is changing with respect to time within 
each treatment group, Student’s pair t test was used and FDR correction was 
applied as previously. A paired (repeatable measures) test was chosen because 
the PCA plot showed that there was considerable inter-subject variability.  
 Finally, a linear mixed-effects (LME) approach was used, which is a more 
powerful statistical method that accounts for the matched nature of the samples 
in this experiment. Such a model treats timepoint and group as “fixed” 
independent variables (i.e., all possible values of each categorical variable are 
fixed and are present in the experiment, or the variables are continuous over a 
known space) and subject as a “random” independent variable (i.e., each subject 
is different and is drawn from a random “subject space”). This type of model has 
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good power to identify genes that change with respect to each fixed effect 
(timepoint, group, or the combination of the two, while accounting properly for the 
random (subject) effect.   
The model is of the same form as the standard linear model, with a 
grouping (“|”) added to indicate the random effect: [expression ~ timepoint + 
group + timepoint:group | subject].  A two-way ANOVA was then used to assign a 
p-value to the timepoint:group term in the model. Separate LME models were 
also created to assess the significance of time within each timepoint group: 
[expression ~ timepoint | subject]. A one-way ANOVA was then used to assign a 
p-value to the timepoint term in the model. FDR correction was applied in the 
same manner as previously to obtain q-values for each model.  
 The number of genes with nominal p values below several different 
thresholds, as well as the numbers of genes expected by chance at each 
threshold, are summarized for each model in the following tables. Bold, italicized 
cells indicate more genes expected than by chance (Tables 5, 6, 7 and 8).  
For the simple linear model and paired t tests, the number of genes below 
each threshold was well below that expected by chance in both halves of the 
study. In the first half of the study, for the LME models, the number of genes at 
each threshold was modest (slightly higher than expected by chance) for the 
inter-group comparison and for the vitamin D2 groups, and substantially higher for 
the vitamin D3 group (Table 5A). Accordingly, there were very few (if any) genes 
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that passed FDR correction in any group other than the vitamin D3 group (Table 
5B). This inter-group difference is especially striking, given that there were many 
more subjects in the mushroom D2 group (n=10) than in the other two groups 
(supplemental D2: n=6; D3: n=4), meaning that the mushroom D2 group should 
have the greatest statistical power to detect differential expression with respect to 
treatment. This suggests that the mushroom vitamin D2 group had a very weak 
effect on differential gene expression and that vitamin D3 treatment had a 
relatively strong effect on differential gene expression.  
A  timepoint within each group 
  timepoint:group MD2 D2 D3 
p threshold expected SLM LME Paired t LME Paired t LME Paired t LME 
0.05 984 363 1409 742 1280 820 1897 859 2331 
0.01 197 53 309 110 234 117 476 158 820 
0.005 98 26 158 48 122 53 266 76 531 
0.001 20 5 35 5 20 9 63 14 161 
 
B   timepoint within each group 
 timepoint:group MD2 D2 D3 
q threshold SLM LME Paired t LME Paired T LME Paired t LME 
0.25 0 11 0 0 0 32 0 875 
0.1 0 5 0 0 0 7 0 109 
0.05 0 1 0 0 0 0 0 13 
0.01 0 0 0 0 0 0 0 0 
Table 5: Differentially expressed genes using the paired t and linear mixed effects (LME) models 
from the first half of the study. (A) p values and (B) FDR corrected q values. 
 In the second half of the study, the number of genes for the paired t test in 
the placebo group was well above that expected by chance (Table 6A). Similarly, 
for the LME models, the number of genes at each threshold was modest (slightly 
higher than expected by chance) for the inter-group comparison and for the 
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vitamin D2 groups, somewhat higher for the vitamin D3 group, and very high for 
the mushroom placebo group. Accordingly, there were few genes that passed 
FDR correction in any group other than the mushroom placebo (Table 6B). This 
indicates that this experiment does not appear to be strongly powered to detect 
an effect of vitamin D supplementation on genome-wide differential gene 
expression, and furthermore, that there is some external variable confounded 
with time in the mushroom powder placebo group that is associated with strong 
differential gene expression.   
A timepoint within each group 
  timepoint:group MP MD2 D2 D3 
p 
threshold 
expe
-cted SLM LME 
Paired 
t LME 
Paired 
t LME 
Paired 
t LME 
Paired 
t LME 
0.05 984 150 1198 2949 5310 496 1255 407 1045 798 2093 
0.01 197 17 270 639 2159 75 309 68 274 42 498 
0.005 98 3 132 293 1381 23 169 28 152 67 286 
0.001 20 1 32 63 430 2 38 7 42 12 82 
 
B   timepoint within each group 
 timepoint:group MP MD2 D2 D3 
q threshold SLM LME Paired t LME Paired t LME Paired t LME Paired t LME 
0.25 0 0 19 6949 0 0 0 23 0 122 
0.1 0 0 1 2538 0 0 0 0 0 1 
0.05 0 0 0 581 0 0 0 0 0 1 
0.01 0 0 0 15 0 0 0 0 0 0 
Table 6: Differentially expressed genes using the paired t and linear mixed effects (LME) models 
from the second half of the study. (A) p values and (B) FDR corrected q values. 
Linear Mixed-Effects Model for Δlog2(25(OH)D):timepoint (Intra-group) 
 To determine whether correcting for change in total vitamin D levels would 
identify more significant differential gene expression with respect to timepoint, 
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another linear mixed-effects model was created in which timepoint and change in 
vitamin D were included as fixed variables and subject was included as a random 
variable: [expression ~ Δlog2[25(OH)D] + timepoint + Δlog2[25(OH)D]: timepoint | 
subject]. Change in log-transformed 25(OH)D levels was used rather than 
Δ25(OH)D in order to account for variation in baseline 25(OH)D levels across 
subjects. Δlog2[25(OH)D] is equivalent to log2[fold(25(OH)D)], i.e. the same 
absolute change in 25(OH)D levels will produce a larger Δlog2[25(OH)D] metric 
for subjects with lower baseline 25(OH)D levels.  
A Δlog2[25(OH)D]:timepoint interaction 
p threshold expected MD2 D2 D3 
0.05 984 1584 3238 4528 
0.01 197 472 1189 2185 
0.005 98 280 751 1611 
0.001 20 87 288 811 
 
B Δlog2[25(OH)D]:timepoint interaction 
q threshold MD2 D2 D3 
0.25 124 2332 5077 
0.1 26 504 2418 
0.05 0 183 1364 
0.01 0 12 449 
Table 7: Differentially expressed genes using the Δlog2[25(OH)D]:timepoint model from the first 
half of the study. (A) p values and (B) FDR-corrected q values.  
A two-way anova was then used to assign a p-value to the 
Δlog2[25(OH)D]:timepoint term in the model, FDR correction was applied, and 
nominal p- and FDR q-values were tabulated as before (Tables 7 and 8). 
In the first half of the study, there were more differentially expressed 
genes at each significance threshold than expected by chance, and in 
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accordance with the inter-group ANOVA results, this was greatest in the vitamin 
D3 group (Table 7). Again, this is striking given that this group had the lowest 
statistical power. It is likely, however, that this model is overfit to the data, given 
the very large number of genes that were differentially expressed with respect to 
vitamin D treatment.  
A Δlog2[25(OH)D]:timepoint interaction 
p threshold expected MP MD2 D2 D3 
0.05 984 2533 3532 5390 6050 
0.01 197 923 1373 2284 2487 
0.005 98 617 869 1594 1653 
0.001 20 240 316 669 620 
 
B Δlog2[25(OH)D]:timepoint interaction 
q threshold MP MD2 D2 D3 
0.25 1144 3084 7338 8569 
0.1 331 695 2669 3613 
0.05 129 224 1227 1309 
0.01 17 30 174 110 
Table 8: Differentially expressed genes using the Δlog2[25(OH)D]:timepoint model from the 
second half of the study. (A) p values and (B) FDR-corrected q values.  
In second half of the study, there were many more differentially expressed 
genes at each significance threshold than expected by chance (Table 8). 
Furthermore, there were fewer genes at each threshold in the mushroom placebo 
group than in the vitamin D treatment groups. However, it is likely that this model 
is overfit to the data, given the very large number of genes that were differentially 
expressed with respect to vitamin D treatment. As there is also a large amount of 
differential expression in the placebo groups, these results should also be 
interpreted with caution. 
	  54 
Heatmaps of Gene Expression 
Heatmaps to show differentially changing gene expression were also 
generated. Prior to assigning colors, the expression values were zero-centered 
within each subject, and then scaled again to a mean of zero and a standard 
deviation of one across all samples (z-normalized). Therefore, red (high 
expression) and blue (low expression) indicate expression values greater than or 
equal to two standard deviations above and below the row-wise mean (white), 
respectively, with brighter colors indicating a stronger change within each 
subject. For the Δlog2[25(OH)D]:timepoint effect, brighter colors indicate greater 
change in vitamin D levels over time.  
Heatmaps were generated from both halves of the study and, at each 
statistical analysis (timepoint:group ANOVA, timepoint ANOVA, and 
Δlog2[25(OH)D]:timepoint ANOVA), demonstrated little cohesion of data. 
Generally, group trends were strongly influenced by a single subject with 
significant differential gene expression between week 0 and week 12. Figures 21 
and 22 depict timepoint:group heapmaps that are representative of the lack of 
cohesion observed on heatmaps generated from all statistical models. 
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Figure 21: Heatmap from the first half of the study of the top 309 genes with the most significant 
differential expression (nominal p < 0.01) with respect to the interaction of timepoint and 
treatment group in the two-way ANOVA (timepoint:group). 
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Figure 22: Heatmap from the second half of the study of to 270 genes with the most significant 
differential expression (nominal p < 0.01) with respect to the interaction of timepoint and 
treatment group in the two-way ANOVA (timepoint:group). 
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Gene Set Enrichment Analysis (GSEA) 
 Gene Set Enrichment Analysis (GSEA, version 2.0.13) was then used to 
identify biological terms, pathways and processes that were overrepresented 
among the genes that were up- or down-regulated with respect to time in each 
treatment group (Subramanian et al, 2005). Briefly, the idea behind GSEA is that 
it determines whether, on the whole, a given set of genes tends to be more up-
regulated or down-regulated in a given comparison (Figure 23). If the set of 
genes is regulated by some biological pathway or process, then a significant 
GSEA result for that gene suggests that the pathway/process is relevant to the 
experimental comparison at hand. GSEA requires two in inputs: a list of all genes 
on a platform that is ranked according to some metric, and a collection of gene 
sets to test (Subramanian et al, 2005).  
 The list of all genes on a platform that is ranked according to some metric 
was generated by using the Entrez Gene ID’s of all genes in the Human Gene 
1.0 ST array, ranked by the signed square root of the likelihood ratio (LR) metric 
derived from the one-way ANOVA for the timepoint term in the LME model 
performed within each treatment group, producing ranked lists (three for the first 
half of the study, four for the second half of the study). Genes for which the LME 
model did not numerically converge (estimate a coefficient for the timepoint term 
in the model) were removed from the list, so the ranked lists are not exactly the 
same length.  
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Figure 23: How GSEA is performed. (A) An expression data set sorted by correlation with 
phenotype, the corresponding heat map, and the gene tags i.e., locations of genes from a set S 
within the sorted list. (B) Plot of the running sum for S in the data set, including the location of the 
maximum enrichment score (ES) and the leading-edge subset (Subramanian et al, 2005).  
 A collection of gene sets was obtained from the publically available 
Molecular Signatures Database (MSigDB version 4.0), which is maintained by the 
same group that developed GSEA (Subramanian et al, 2007). Gene sets 
corresponding to biological pathways, locations or functions are derived from the 
following public databases: Kyoto Encyclopedia of Genes and Genomes (KEGG), 
Gene Ontology (GO), Biocarta, and Reactome. Additionally, sets of genes were 
also included that are computationally predicted to contain transcription factor or 
microRNA binding sites in their promoters or 3’ UTRs, respectively. However, 
these motifs may or may not be associated with known regulators.  
 For each ranked list, GSEA algorithm tests each gene set in turn to 
determine whether its members are distributed nonrandomly within the ranked 
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lists. As seen in Figure 20, it then assigns a p-value to each gene set based on 
how skewed the distribution of the gene set is towards the up- or down-regulated 
end of the ranked lists (weighted by ranking the metric, so that the genes at the 
extreme end of the ranked list have more importance in computing the p-value) 
(Subramanian et al, 2007). FDR correction was applied as before, and FDR q-
values were tabulated as before. In Tables 9, 10 and 11, FDR q-values closer to 
zero (dark green) indicate stronger association, while paler green and white 
indicate little association.   
The GSEA results were compared between halves of the study. Using a 
cutoff FDR q-value of 0.1, approximately 2652 gene sets, or pathways, were 
narrowed down to 17 comparable sets in mushroom D2 (Table 9), 2 in 
supplemental D2 (Table 10), and 19 in supplemental D3 (Table 11).  Of the 17 
gene sets shared in the mushroom D2 group, 10 also had significant p-values in 
the mushroom powder group, indicating the possibility of mushroom-specific 
transcriptional regulation. 8 of the 10 gene sets were involved in RNA metabolism 
or degradation. Of the other two, REACTOME_TRANSLATION could potentially 
be related, though RECEPTOR_MEDIATED_ENDOCYTOSIS does not appear to 
follow the trend. Of the 7 gene sets without significant changes in activity in the 
mushroom powder group, none are related to RNA and most have low q-values 
in the supplemental D2 group from the first half and supplemental D3 group from 
the second half.  
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First half Second half 
Name of gene set MD2 D2 D3 MP MD2 D2 D3 
REACTOME_GLYCOSPHINGOLIPID_ 
METABOLISM 0.048 0.022 1.000 0.912 0.002 0.861 0.135 
KEGG_OTHER_GLYCAN_DEGRADATION 0.069 0.061 1.000 0.439 0.014 0.221 0.344 
CARBOHYDRATE_CATABOLIC_ 
PROCESS 0.029 0.359 0.974 0.968 0.015 0.976 0.210 
HYDROLASE_ACTIVITY_HYDROLYZING_
O_GLYCOSYL_COMPOUNDS 0.046 0.190 1.000 0.966 0.016 0.862 0.527 
CELLULAR_CARBOHYDRATE_ 
CATABOLIC_PROCESS 0.034 0.244 0.966 0.963 0.018 0.993 0.156 
REACTOME_MEMBRANE_TRAFFICKING 0.052 0.071 1.000 0.434 0.040 0.791 0.003 
RHO_PROTEIN_SIGNAL_TRANSDUCTION 0.046 0.218 0.998 0.755 0.075 0.944 0.944 
*REACTOME_METABOLISM_OF_RNA 0.010 1.000 0.447 0.000 0.005 0.527 0.000 
*KEGG_RNA_DEGRADATION 0.011 1.000 0.823 0.000 0.093 0.295 0.000 
*REACTOME_DEADENYLATION_ 
DEPENDENT_MRNA_DECAY 0.017 1.000 1.000 0.001 0.028 0.879 0.000 
*REACTOME_METABOLISM_OF_MRNA 0.028 1.000 0.319 0.000 0.014 0.869 0.000 
*RECEPTOR_MEDIATED_ 
ENDOCYTOSIS 0.047 1.000 0.837 0.039 0.085 0.796 0.925 
*REACTOME_DEADENYLATION_OF_ 
MRNA 0.049 1.000 0.781 0.040 0.093 0.473 0.009 
*REACTOME_METABOLISM_OF_MRNA 0.028 1.000 0.319 0.000 0.014 0.869 0.000 
*REACTOME_TRANSLATION 0.001 1.000 0.000 0.000 0.062 0.904 0.000 
*KEGG_RNA_DEGRADATION 0.011 1.000 0.823 0.000 0.093 0.295 0.000 
*REACTOME_ACTIVATION_OF_THE_ 
MRNA_UPON_BINDING_OF_THE_CAP_ 
BINDING_COMPLEX_AND_EIFS_AND_ 
SUBSEQUENT_BINDING_TO_43S 
0.008 0.725 N/A 0.000 0.089 0.475 0.000 
Table 9: Gene set expression analysis (GSEA) for Mushroom D2 treatment group. Using a FDR q-
value cutoff of 0.1, gene sets were sorted by mushroom D2 in one half of the study. FDR q-values 
closer to 0 (dark green) indicate stronger association, while paler green and white indicate little 
association. (*: gene sets with FDR q-values less than 0.1 also in the mushroom powder 
treatment group). 
 Between the supplemental D2 treatment groups, only 2 gene sets had 
FDR q-values below 0.1, indicating strong discord between halves of the study 
(Table 9). Similarly to the gene expression results, the lack of cohesion between 
halves of the study in this group could indicate that the n is too small or that there 
are other confounding variables affecting this group. REACTOME_RECYCLING_ 
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PATHWAY_OF_L1 is a neuronal development gene set and 
KEGG_LYSINE_DEGRADATION is a general pathway found in many 
mammalian cell types. 
 First half Second half 
Name of gene set MD2 D2 D3 MP MD2 D2 D3 
REACTOME_RECYCLING_PATHWAY_OF_L1 0.219 0.062 0.473 0.866 0.532 0.068 0.042 
KEGG_LYSINE_DEGRADATION 0.974 0.096 0.977 0.001 1.000 0.058 0.013 
Table 10: Gene set expression analysis (GSEA) for the supplemental D2 treatment group. Using a 
FDR q-value cutoff of 0.1, gene sets were sorted by supplemental D2 in the first half of the study. 
FDR q-values closer to 0 (dark green) indicate stronger association, while paler green and white 
indicate little association. 
 Supplemental D3 had the most correspondence between halves of the 
study, with 19 gene sets showing q-values of less than 0.1 (Table 11). Of the 
significant gene sets, many were involved in replication, transcription and 
translation pathways, but they did not overlap with gene sets significant to both 
mushroom powder and mushroom D2 treatment groups or to the supplemental D2 
treatment group. The only exception was REACTOME_TRANSLATION, which 
was significant in all groups except supplemental D2 in both halves of the study. 
Of note, REACTOME_INFLUENZA_VIRAL_RNA_TRANSCRIPTION_ 
AND_REPLICATION was significant in the supplemental D3 group and, as an 
immune-related pathway, could be important. However, the study was conducted 
over the winter months, and this could simply be an indication of flu season.  
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 First half Second half Name of gene set MD2 D2 D3 MP MD2 D2 D3 
REACTOME_RNA_POL_I_ 
TRANSCRIPTION 0.985 1.000 0.000 0.695 0.936 0.000 0.011 
REACTOME_TRANSLATION 0.001 1.000 0.000 0.000 0.062 0.904 0.000 
REACTOME_3_UTR_MEDIATED_ 
TRANSLATIONAL_REGULATION 0.000 0.858 0.000 0.000 0.138 0.941 0.000 
REACTOME_SRP_DEPENDENT_ 
COTRANSLATIONAL_PROTEIN_ 
TARGETING_TO_MEMBRANE 
0.000 1.000 0.000 0.000 0.183 1.000 0.000 
REACTOME_RNA_POL_I_PROMOTER_
OPENING 0.780 1.000 0.000 0.004 1.000 0.000 0.080 
KEGG_RIBOSOME 0.000 0.828 0.001 0.000 0.248 1.000 0.000 
REACTOME_PACKAGING_OF_ 
TELOMERE_ENDS 0.808 0.736 0.001 0.012 1.000 0.000 0.026 
REACTOME_FORMATION_OF_THE_ 
TERNARY_COMPLEX_AND_ 
SUBSEQUENTLY_THE_43S_COMPLEX 
0.004 0.330 0.001 0.001 0.435 0.735 0.000 
REACTOME_PEPTIDE_CHAIN_ 
ELONGATION 0.000 0.745 0.001 0.000 0.468 1.000 0.001 
REACTOME_TELOMERE_ 
MAINTENANCE 0.973 1.000 0.003 0.753 1.000 0.000 0.001 
REACTOME_DEPOSITION_OF_NEW_CE
NPA_CONTAINING_NUCLEOSOMES_AT
_THE_CENTROMERE 
0.933 1.000 0.003 0.758 0.716 0.000 0.004 
STRUCTURAL_CONSTITUENT_OF_ 
RIBOSOME 0.001 0.548 0.013 0.001 0.721 1.000 0.007 
REACTOME_INFLUENZA_VIRAL_RNA_ 
TRANSCRIPTION_AND_REPLICATION 0.000 0.751 0.021 0.000 0.411 1.000 0.000 
REACTOME_MEIOTIC_ 
RECOMBINATION 0.989 1.000 0.041 0.102 1.000 0.000 0.027 
REACTOME_RNA_POL_I_RNA_POL_III_
AND_MITOCHONDRIAL_ 
TRANSCRIPTION 
0.986 1.000 0.054 0.146 0.937 0.002 0.000 
REACTOME_RESPIRATORY_ELECTRON
_TRANSPORT_ATP_SYNTHESIS_BY_CH
EMIOSMOTIC_COUPLING_AND_HEAT_ 
PRODUCTION_BY_UNCOUPLING_ 
PROTEINS_ 
0.961 0.588 0.055 0.000 0.000 0.994 0.000 
REACTOME_CHROMOSOME_ 
MAINTENANCE 0.771 1.000 0.067 0.340 1.000 0.004 0.002 
REACTOME_MEIOTIC_SYNAPSIS 0.922 0.870 0.074 0.297 1.000 0.000 0.069 
REACTOME_METABOLISM_OF_ 
PROTEINS 0.262 1.000 0.076 0.000 0.116 0.867 0.000 
Table 11: Gene set expression analysis (GSEA) for the supplemental D3 treatment group. Using a 
FDR q-value cutoff of 0.1, gene sets were sorted by supplemental D3 in the first half of the study. 
FDR q-values closer to 0 (dark green) indicate stronger association, while paler green and white 
indicate little association. 
  
	  63 
DISCUSSION 
Response to Different Vitamin D Treatments 
 Reports are mixed on whether vitamin D2 has the same bioavailability and 
efficacy as vitamin D3. Biancuzzo et al showed comparable rises in 25(OH)D with 
vitamin D2 and vitamin D3 supplementation (Biancuzzo et al, 2010).  Holick et al 
also showed that vitamin D2 is as effective as vitamin D3 at the same 1000 IU/day 
dose (Holick et al, 2008). Furthermore, they did not observe a decrease in 
25(OH)D3 levels in subjects taking supplemental vitamin D2 (Holick et al, 2008), 
which is consistent with our findings. However, a meta-analysis of studies 
comparing vitamin D3 and vitamin D2 from 1966 to 2011 concluded that vitamin 
D3 is more effective at raising 25(OH)D levels than vitamin D2 (Tripkovic et al, 
2012).  A bolus dose of vitamin D3 had significantly stronger 25(OH)D response 
when compared with vitamin D2, but the same was not observed in daily 
supplementation (Tripkovic et al, 2012). Their conclusions suggested opting for 
vitamin D3 over vitamin D2, instead of declaring one clearly superior, as well as 
citing the need for more robust trials to further explore the phenomena (Tripkovic 
et al, 2012).  
In this study, subjects that ingested 2000 IU of vitamin D3 had a 
significantly higher rise in total serum 25(OH)D levels (114.2 ± 46.8%) when 
compared to both supplemental D2 (60.2 ± 37.8%) and mushroom vitamin D2 
(53.2 ± 49.8%). These differences could be due to different vitamin D content in 
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the capsules. HPLC assay of the supplement content is summarized in Table 2. 
The supplements contained the expected vitamin D2 or vitamin D3. However, 
each supplement contained more than stated on the label, which is expected. 
Mushroom D2 capsules contained 2938 ± 91 IU/capsule, 42.3% higher than the 
stated 2000 IU/capsule. The vitamin D2 supplements had an average of 2325 ± 
203 IU/capsule,16.3% above the stated value. Vitamin D3 supplements had an 
average content of 2547 ± 183 IU/capsule, 27.4% higher than stated (Table 12). 
For Class I nutrients, such as vitamins, the manufacturer is only required 
to have at least 100% of the stated value in the product. In milk, vitamin D is 
fortified with 400 IU/quart, with an allowed maximum of 600 IU/quart for shelf life 
purposes. One organization that certifies content of products, the US 
Pharmacopeial, requires that compounded pills contain 90 to 110% of the active 
ingredient (US Pharmacopeia, 2012). However, LeBlanc et al showed that only 
1/3 of the tested over the counter supplements vitamin D3 met this criteria 
(Leblanc et al, 2013), indicating that the higher content detected in the mushroom 
D2 and supplemental D3 capsules is a common phenomena.  
The high average mushroom D2 content (2938 ± 91 IU/capsule) explains 
the average 25(OH)D2 increase of 18.7 ± 8.0 ng/ml. However, since 25(OH)D3 
decreased significantly by 7.1 ± 5.0 ng/ml (p < 0.01), the total 25(OH)D did not 
increase to the same degree as 25(OH)D2. If the 25(OH)D3 did not concurrently 
decrease, the change in total 25(OH)D in the mushroom D2 group would exhibit a 
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trend similar to the vitamin D3 supplementation group. In contrast, 25(OH)D3 in 
the supplemental D2 group did not change significantly (p = 0.42). Even so, the 
increases in total 25(OH)D, 25(OH)D2 and 25(OH)D3 exhibited no statistical 
significance between mushroom D2 and supplemental D2 groups, in a one-way 
ANOVA with a post-hoc Tukey test, which indicates that supplemental D2 and 
mushroom D2 were equally effective at raising subjects’ vitamin D status. In the 
same statistical manner, the change in 25(OH)D2 and 25(OH)D3 were found to be 
significant between supplemental D3 and mushroom D2, as well as between 
supplemental D3 and supplemental D2, as expected due to the fact that they are 
receiving distinct forms of vitamin D. However, neither mushroom D2 nor 
supplemental D2 demonstrated significance in total 25(OH)D when compared 
with supplemental D3, further supporting that mushroom D2 and supplemental D2 
are just as effective at raising vitamin D status as supplemental D3.  
The decrease in 25(OH)D3 levels in the group that received mushroom 
vitamin D2 was most likely due to the increase of vitamin D2 in circulation and the 
subsequent hydroxylation of vitamin D2 in the liver. Additionally, the decrease in 
25(OH)D3 in the mushroom D2 group is consistent with findings regarding 
consumption of vitamin D2 in mushrooms (Stephensen et al, 2012). 
The mushroom powder capsules had no vitamin D2 or vitamin D3 content 
(Table 2). In the vitamin D response measured by 25(OH)D levels, the mushroom 
powder served well as a placebo, with no significant change found in total 
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25(OH)D, 25(OH)D2 or 25(OH)D3. Furthermore, subjects in the placebo 
mushroom powder group did not exhibit a decrease in 25(OH)D3, indicating that 
the presence of mushrooms was not the cause of the trend in the mushroom 
vitamin D2 group. Thus, it could be a statistical fluke or some subjects in the 
supplemental vitamin D2 may have obtained vitamin D3 through cutaneous 
production from sun exposure. 
 
D2 D3 
Mushroom D2 (IU/capsule) 2938 ± 91 ND 
     Range (IU/capsule) 2846 - 3047 
      IU D2 to increase 25(OH)D2 by 1 ng/ml (IU/ng) 163   
     Change in 25(OH)D2 per 100 IU (ng) 0.61  
D2 (IU/capsule) 2325 ± 203 ND 
     Range (IU/capsule) 2152 - 2654 
      IU D2 to increase 25(OH)D2 by 1 ng/ml (IU/ng) 205   
     Change in 25(OH)D2 per 100 IU (ng) 0.49  
D3 (IU/capsule) ND 2547 ± 183 
     Range (IU/capsule) 
 
2247 - 2749 
     IU D3 to increase 25(OH)D3 by 1 ng/ml (IU/ng)   113 
     Change in 25(OH)D3 per 100 IU  0.89 
Table 12: Ability of 100 IU of each treatment to increase 25(OH)D2 or 25(OH)D3, respectively. 
 To calculate the effectiveness of the supplements at raising a subject’s 
vitamin D status, the capsule content (IU) was divided by the change in total 
25(OH)D (ng). Generally, it is accepted that 100 IU/day raises 25(OH)D levels by 
~1 ng/week (Heaney et al, 2003). A smaller value (IU/ng) indicates that more IU 
of the vitamin D contained in the three kinds of capsules was required to increase 
25(OH)D by 1 ng/ml. Therefore, the mushroom D2 raised 25(OH)D by 0.37 ng 
with every 100 IU consumed, supplemental D2 raised 25(OH)D by 0.51 ng per 
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every 100 IU consumed, and supplemental vitamin D3 raised 25(OH)D by 0.87 
per every 100 IU consumed (Table 12).  
Additionally, 163 IU of mushroom D2 raised 25(OH)D2 by 1 ng, much less 
than the 205 IU/ng 25(OH)D2 required in supplemental D2 (Table 12). This 
explains why a larger change in 25(OH)D2 was observed in the mushroom D2 
group (18.0 ng/ml) versus the supplemental D2 group (12.4 ng/ml). 
Changes in Gene Expression 
There is a substantial body of evidence showing the immunomodulatory 
effect of mushrooms (Akramiene et al, 2006; Chan et al, 2008; Yu et al, 2008; 
Murphy, et al, 2010; Ren et al, 2012; Xu et al, 2013; 131, 135), even at the 
transcription level in white blood cells (Smiderle et al, 2010). Therefore, in the 
context of gene expression, mushroom powder may only serve as a control to 
mushroom vitamin D2, as they should contain the same compounds with the 
exception of vitamin D2.  
Subject Initial total 25(OH)D 
Final total 
25(OH)D Δ total 25(OH)D Δ25(OH)D2 Δ 25(OH)D3 
32 34.3 33.8 -0.5 17.5 -17.8 
34 27.0 38.5 11.5 17.5 -6.5 
35 27.6 25.9 -1.7 4.8 -6.5 
54 18.8 56.2 37.3 38.4 -1.1 
65 28.6 33.3 4.6 15.6 -10.9 
Table 13: Subjects in the mushroom D2 group from the second half of the study.  
With FDR correction, the mushroom powder group had over 6000 genes 
differentially expressed (1/3 of genes tested), while the mushroom D2 showed 
zero (Table 5B). This might be due to poor randomized distribution of the 
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mushroom D2 group between the first and second halves of the study. In order to 
include 5 subjects in the second half analysis, subjects with undesirable vitamin 
D responses had to be included (Table 13).  Four of the five subjects had initial 
total 25(OH)D levels of > 27.0 ng/ml, and one subject was vitamin D sufficient. 
Two subjects (32 and 35) had slight negative changes in total 25(OH)D, as 
opposed to rises comparable to the average in the group (10.9 ng/ml). 
Additionally, one of the five subjects had a change in total 25(OH)D of 37.3 
ng/ml. These factors might contribute to the lack of statistically significant genes 
with changes differential expression.  
When compared to the results found by Hossein-nezhad et al, none of the 
300 genes previously found significant had strong differential expression 
(Hossein-nezhad et al, 2012). Due to the few genes with strong FDR-corrected 
differential changes in gene expression across the whole study, this is not 
unexpected. Additionally, the statistician who ran the analyses in Hossein-nezhad 
was no longer affiliated with the Microarray Core, so different statisticians with 
potentially varied methodology ran the analyses.  
Comparing gene expression and GSEA results with other studies showed 
a similar lack correlation. Notably, the biomarker CD14 identified by Carlberg et 
al had high log2 expression in all groups, but also at both time points, indicating 
little effect of vitamin D treatment (Carlberg et al, 2013). The other biomarker, 
THBD, also showed consistent, moderate expression with little change from 
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baseline to end in all groups. However, VDR expression showed little differential 
change in expression in all groups, which is consistent with previous 
observations (Carlberg et al, 2013; Tarroni et al, 2012). 
  In conclusion, mushroom D2, supplemental D2 and supplemental D3 were 
all effective in raising subjects’ vitamin D status. Due to various confounding 
factors and a low n, changes in gene expression and pathways were difficult to 
discern. However, mushroom powder and mushroom D2 supplementation were 
observed to have strong effects on pathways involved in RNA activation and 
degradation. Further studies will help elucidate the relationships between vitamin 
D status, mushroom supplementation, and differential gene expression.  
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